The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
OTHER

Metformin Monotherapy

Participants in this group (n = 30) received metformin alone, administered in a daily dose of 1000 to 2000 mg divided into two doses, over a period of four weeks.

OTHER

Metformin combined with probiotic (Normia® Jadran Galenski Laboratory) supplementation

Participants (n = 30) received metformin (1000-2000 mg/day, divided in two doses) combined with a probiotic supplement (1 capsule three times daily) over a four-week period.

OTHER

Triple therapy - metformin, probiotic and ursodeoxycholic acid (Bilexin®, Bosnalijek)

Participants in this group (n = 30) were treated with a combination of metformin (1000 - 2000 mg/day), a probiotic (1 capsule three times daily) and ursodeoxycholic acid (UDCA, 1 capsule (250mg) three times daily) for four weeks.

Trial Locations (1)

78000

Public Health Institution Dom zdravlja Banja Luka, Banja Luka

All Listed Sponsors
lead

University of Banja Luka

OTHER

NCT07072949 - The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin | Biotech Hunter | Biotech Hunter